Working… Menu

Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04382924
Recruitment Status : Completed
First Posted : May 11, 2020
Last Update Posted : July 21, 2021
Novotech (Australia)
Information provided by (Responsible Party):
Algernon Pharmaceuticals

Brief Summary:

The purpose of this adaptive trial is to determine the clinical efficacy of Ifenprodil in the treatment of patients infected with COVID-19. This Protocol is largely based on the recommendations of the WHO R&D Blueprint Clinical Trials Expert Group COVID-19 Therapeutic Trial Synopsis, and associated Master Protocol.

The choice of the primary outcome measure will be determined by a pilot study of the first 150 subjects. Subject clinical status (on a 7-point ordinal scale) at day 15 in treatment versus the control group is the default primary endpoint.

Condition or disease Intervention/treatment Phase
COVID Drug: NP-120 (Ifenprodil) Phase 2 Phase 3

Detailed Description:

NP-120 (Ifenprodil) is an N-methyl-D-Aspartate (NDMA) inhibitor that is specific for the NR2B subunit of the NMDA Receptor. The NMDA receptor, and specifically the NR2B subunit, is involved in glutamate signaling, and is expressed on both neutrophils and T cells. In the case of neutrophils, activation of the NMDA receptor can (1) result in expression of CD11b which targets neutrophils via ICAM-1 to areas of inflammation, and (2) trigger the autocrine release of glutamate. In the case of T-cells, activation of T cells via glutamate can cause (1) T cell proliferation and, (2) the release of cytokines. The activation of T cells and cytokine release can be blocked in vitro by the addition of Ifenprodil. As such it could be a potent anti-inflammatory agent.

Ifenprodil was discovered by a genome wide RNAi assay to uncover gene targets associated with cytoprotective activity against highly pathogenic H5N1 influenza, specifically by preserving cell viability in vitro. When tested in a murine model of H5N1, the drug at clinically relevant doses: (1) improved survivability from 0% at day 6 to 40% day 14 post-infection, (2) the drug significantly reduced edema and lung injury score and (3) reduced infiltrating T cells, neutrophils and NK cells and attenuated the 'cytokine storm'. The mortality rate of H5N1 in humans is >50%, whereas the mortality rate of COVID-19 infected patients is < 5%, and both viruses cause acute lung injury and share similar pulmonary pathologies. NP-120 has also been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of idiopathic pulmonary fibrosis, a complication which can occur after a respiratory virus infection.

Based on the fact that H5N1 has a significantly higher mortality rate than COVID-19 but still shares similar lung pathologies, Algernon Pharmaceuticals believes Ifenprodil could reduce lung injury associated with COVID-19 infection, thereby improving lung function and accelerating patient recovery.

The purpose of this Phase 2b/3 trial is to determine the safety and efficacy of NP-120 in the treatment of COVID-19 infection.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 168 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease
Actual Study Start Date : August 5, 2020
Actual Primary Completion Date : December 24, 2020
Actual Study Completion Date : January 26, 2021

Arm Intervention/treatment
Experimental: Treatment Arm A
NP-120 (Ifenprodil) 20 mg TID + Standard of Care
Drug: NP-120 (Ifenprodil)
Ifenprodil, 20 mg TID Ifenprodil, 40 mg TID

No Intervention: Control Arm
Standard of Care only
Experimental: Treatment Arm B
NP-120 (Ifenprodil) 40 mg TID + Standard of Care
Drug: NP-120 (Ifenprodil)
Ifenprodil, 20 mg TID Ifenprodil, 40 mg TID

Primary Outcome Measures :
  1. Patient clinical status (on the WHO 7-point ordinal scale) at day 15 in IP versus SOC control group patients: [ Time Frame: Day 15 ]
    1. Not hospitalized, no limitations on activities
    2. Not hospitalized, limitation on activities
    3. Hospitalized, not requiring supplemental oxygen
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, on non-invasive ventilation or high flow oxygen devices
    6. Hospitalized, on invasive mechanical ventilation or ECMO
    7. Death

Secondary Outcome Measures :
  1. Status on an ordinal scale assessed daily while hospitalized and on days 15 and 28 in IP versus control group patients [ Time Frame: Days 1 through 28 ]
  2. NEWS assessed days 3, 5, 8 ,11 daily while hospitalized and on days 15 and 29 in IP versus control group patients [ Time Frame: Days 3, 5, 8, 11, 25, 29 ]
  3. Rate of mechanical ventilation in IP versus control group patients [ Time Frame: Day 15, 28 ]
  4. Duration of mechanical ventilation (if applicable) in IP versus control group patients [ Time Frame: Day 15, 28 ]
  5. Duration of supplemental oxygen in IP versus control group patients [ Time Frame: Day 15, 28 ]
  6. Time to return to room pressure (SpO2 > 94%) on room air [ Time Frame: Day 15, 28 ]
  7. Duration in ICU (if applicable) in IP versus control group patients [ Time Frame: Day 15, 28 ]
  8. Rate of Mortality in IP versus control group patients [ Time Frame: Day 15, 28 ]
  9. Duration of hospitalization in IP versus control group patients [ Time Frame: Day 15, 28 ]
  10. Time to discharge in IP versus control group patients [ Time Frame: Day 15, 28 ]
  11. Effect on the rate of change of partial pressure of oxygen (PaO2) and PaO2/FiO2 ratio taken at baseline and measured once daily up to 2 weeks of treatment in IP versus control group patients [ Time Frame: Up to day 15, day 28 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female subjects aged ≥18 years of age
  2. Confirmed coronavirus infection

    1. Positive real-time fluorescence polymerase chain reaction of the patient's respiratory or blood specimens for COVID-19 nucleic acid
    2. Viral gene sequences in respiratory or blood specimens that are highly homologous to COVID-19
    3. Any other diagnostic test accepted by local regulatory authorities
  3. Must be hospitalized and requiring supplemental oxygen, or on non-invasive ventilation or high flow oxygen devices (Score of 4 or 5 on WHO Ordinal Clinical Scale)
  4. Female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception (e.g. oral contraceptives, intrauterine device, diaphragm plus spermicide) from the time of screening and must agree to continue using such precautions for 90 days after the final dose of study drug(s)
  5. Non-sterilized males who are sexually active with a female partner of childbearing potential must use condom plus spermicide from day 1 through 90 days after receipt of the last dose of study drug(s)
  6. Subjects (or reasonable legal designate) must have the capacity to understand, sign and date a written, informed consent form and any required authorization prior to initiation of any study procedures

Exclusion Criteria:

  1. Patients with vasodilatory shock, orthostatic hypotension, hypotension, or tachycardia at screening/baseline
  2. Patients experiencing cerebral hemorrhage or cerebral infarction at baseline
  3. ALT/AST > 5 times the upper limit of normal; Child-Pugh Score 10 to 15
  4. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30)
  5. Patients on mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
  6. Patients taking droxidopa
  7. Pregnant and lactating women and those planning to get pregnant
  8. Known or suspected allergy to the trial drug or the relevant drugs given in the trial
  9. Presence of other disease that may interfere with testing procedures or in the judgement of the Investigator may interfere with trial participation or may put the patient at risk when participating in this trial
  10. Know inability of patient to comply with the protocol for the duration of the study
  11. Involvement in a clinical research study within 4 weeks prior to screening and/or prior enrollment in the study or plan to participate in another interventional clinical trial during the study period. Participation in observational registry studies is permitted.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04382924

Layout table for location information
United States, Florida
Westchester Research Center
Miami, Florida, United States, 33155
United States, Illinois
Affinity Health - Loretto Hospital
Chicago, Illinois, United States, 60644
United States, Missouri
Heartland Regional Medical Center
Saint Joseph, Missouri, United States, 64507
United States, Ohio
Promedica Health: Toledo Hospital and BayPark Hospital
Toledo, Ohio, United States, 43606
Australia, Queensland
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia, 4102
Australia, Victoria
Royal Melbourne Hospital
Parkville, Victoria, Australia, 3050
Makati Medical Center
Manila, Philippines
Philippine General Hospital
Manila, Philippines
Lung Center of the Philippines
Quezon City, Philippines
National Institute of Infectious Diseases
Bucharest, Romania, 021105
Sponsors and Collaborators
Algernon Pharmaceuticals
Novotech (Australia)
Layout table for additonal information
Responsible Party: Algernon Pharmaceuticals Identifier: NCT04382924    
Other Study ID Numbers: AGN120-3
First Posted: May 11, 2020    Key Record Dates
Last Update Posted: July 21, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Vasodilator Agents
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents